Phase II single-arm clinical study of teriprizumab combined with low-dose paclitaxel for injection (albumin-bound) in the treatment of advanced gastric cancer that failed first-line treatment and advanced colorectal cancer that failed standard treatment

Interventions: Patients with advanced gastric cancer group:teriprizumab combined with low-dose paclitaxel for injection (albumin-bound);Patients with advanced colorectal cancer group:teriprizumab combined with low-dose paclitaxel for injection (albumin-bound)
Primary outcome(s): Progression free survival
Study Design: Factorial